Where Chinese Investors Meet Global Investment News and Opportunities

中國投資者探索環球投資新聞及機遇

Cerveau Technologies, Inc. to Support a First Clinical Study in Asia of a Novel Biomarker of Alzheimer’s Disease

Cerveau Technologies, Inc. to Support a First Clinical Study in Asia of a Novel Biomarker of Alzheimer’s Disease

Cerveau Technologies Inc. today announced that the Memory Aging and Cognition Centre (MACC) at the National University Health System (NUHS) in Singapore has initiated a study with an early stage imaging agent [18F]MK-6240 to be used in Positron...

Read more
Wuxi AppTec, Juno Therapeutics Hope to Release CAR-T Cancer Treatment by 2020

Wuxi AppTec, Juno Therapeutics Hope to Release CAR-T Cancer Treatment by 2020

A joint venture between China’s largest small molecule pharma researcher Wuxi AppTec Group and leading American pharma Juno Therapeutics plan to bring a new cancer immunotherapy to the market by 2020. JW Biotechnology will make the drug at...

Read more
Alibaba’s Healthcare Tech Takes Aim at Flu Season in Macao

Alibaba’s Healthcare Tech Takes Aim at Flu Season in Macao

Chinese e-commerce giant Alibaba Group Holding is putting its artificial intelligence tech to work in Macao, where it hopes to provide a new way of predicting and preventing endemic diseases. Hangzhou-based Alibaba fed machine learning tools with...

Read more
Global Cannabis Market Projected to Grow as the Medical Segment Is Slated to Dominate

Global Cannabis Market Projected to Grow as the Medical Segment Is Slated to Dominate

Cannabis continues its spread around the world, with countries like Germany and Australia already implementing cannabis for medical purposes. Now, as countries begin to legalize cannabis, more regions are expected to follow. According to data...

Read more
Innovent Sees Positive Data from China Phase III Trial of Avastin Biosimilar

Innovent Sees Positive Data from China Phase III Trial of Avastin Biosimilar

Suzhou Innovent Biologics reported its Avastin biosimilar produced positive results in two China clinical trials. IBI305, a VEGF inhibitor, met its primary endpoints in two randomized clinical trials that compared the candidate to Roche’s...

Read more
WuXi Biologics Congratulates Tychan on First-in-Class Monoclonal Antibody for Yellow Fever after Record 7 Months of Development

WuXi Biologics Congratulates Tychan on First-in-Class Monoclonal Antibody for Yellow Fever after Record 7 Months of Development

WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company that offers end-to-end solutions for biologics discovery, development and manufacturing, today congratulates its partner Tychan for dosing of first...

Read more
WuXi AppTec Lists H Shares on the Hong Kong Stock Exchange

WuXi AppTec Lists H Shares on the Hong Kong Stock Exchange

WuXi AppTec Co., Ltd. (“WuXi AppTec” or “the Company”; Stock code: 603259.SH/2359.HK) today announced the listing of approximately 116 million H-shares on the Main Board of the Hong Kong Stock Exchange. Based on the offer price of HK$68 per...

Read more
Koios Secures Vendor Agreement With Retail Giant GNC

Koios Secures Vendor Agreement With Retail Giant GNC

Koios Beverage Corp. (CSE: KBEV; OTC: KBEVF) (the “Company” or “Koios“), is pleased to announce it has signed a vendor agreement with GNC Holdings, Inc. (GNC), a leading global health and wellness brand with thousands of retail stores across the...

Read more
Lilly and AC Immune Sign Deal to Develop Tau-Based Treatments for Alzheimer’s

Lilly and AC Immune Sign Deal to Develop Tau-Based Treatments for Alzheimer’s

Eli Lilly and Company, headquartered in Indianapolis, and AC Immune SA, based in Lausanne, Switzerland, entered a license and collaboration deal to research and develop tau aggregation inhibitor compounds for the treatment of Alzheimer’s and...

Read more
Lonza to Establish Strategic Biomanufacturing Base in China Using GE Healthcare Solution

Lonza to Establish Strategic Biomanufacturing Base in China Using GE Healthcare Solution

New biologics facility, scheduled to be operational in 2020, will provide development and manufacturing facilities from early- to late-clinical and early-commercial stages GE Healthcare’s off-the-shelf biologics factory, KUBio, will provide the...

Read more
Zai Lab’s NDA for PARP Inhibitor Accepted for China Review

Zai Lab’s NDA for PARP Inhibitor Accepted for China Review

Zai Lab of Shanghai announced that the China National Medical Products Administration (NMPA) accepted its NDA for Zejula (niraparib), a novel Category 1 PARP1/2 drug — the first Zai NDA submission accepted in China. The candidate is...

Read more
Newstrike and Neal Brothers complete agreement to create co-branded specialty food products company

Newstrike and Neal Brothers complete agreement to create co-branded specialty food products company

Newstrike Brands Ltd. (TSX-V:HIP) (“Newstrike” or the “Company“) is pleased to announce that it has completed its previously-announced transaction with Peter Neal and Chris Neal and their company, Neal Brothers Inc. (“Neal Brothers“) to create a...

Read more
Do NOT follow this link or you will be banned from the site!